Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs iShares Semiconductor ETF (SOXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs iShares Semiconductor ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.75 (market cap $39.89B), while iShares Semiconductor ETF trades at $565.29. The key difference: iShares Semiconductor ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SOXX | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Sector/Thematic |
52-Week High | $491.22 | $655.01 |
52-Week Low | $278.09 | $236.93 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SOXX trades at $581.13, down 0.1% with neutral technical signals. The semiconductor ETF has surged 93.3% YTD through July 6, 2026, driven by AI demand, but faces recent volatility with an 11% drop over the past week. Moving averages remain bullish while oscillators signal neutrality. Key support sits at $576 with resistance at $591.
Outlook remains mixed with strong AI-driven growth potential offset by near-term volatility. Michael Burry's short position and hedge fund selling create headwinds, while JPMorgan recommends buying the dip. The sector faces rotation risk as investors may pivot to hyperscalers according to Morgan Stanley analysis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About iShares Semiconductor ETF
SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →
